NASDAQ:MRTXMirati Therapeutics Stock Price, Forecast & News

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRTX stock has increased by 31.3% and is now trading at $101.62. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mirati Therapeutics.

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Mirati Therapeutics.

Mirati Therapeutics Inc (NASDAQ:MRTX) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($2.02) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.66) by $0.36. The biotechnology company earned $0.27 million during the quarter, compared to analyst estimates of $0.29 million. Mirati Therapeutics had a negative net margin of 10,983.84% and a negative return on equity of 53.25%. The business's revenue for the quarter was down 78.5% compared to the same quarter last year. View Mirati Therapeutics' earnings history.

17 equities research analysts have issued 12-month price targets for Mirati Therapeutics' shares. Their forecasts range from $83.00 to $151.00. On average, they anticipate Mirati Therapeutics' share price to reach $113.56 in the next year. This suggests a possible upside of 11.8% from the stock's current price. View analysts' price targets for Mirati Therapeutics.

Media stories about MRTX stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mirati Therapeutics earned a news impact score of -2.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutMirati Therapeutics.

Some companies that are related to Mirati Therapeutics include BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Catalent (CTLT), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Mylan (MYL) and ACADIA Pharmaceuticals (ACAD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), DexCom (DXCM), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Paypal (PYPL), Skyworks Solutions (SWKS), Advanced Micro Devices (AMD) and Exelixis (EXEL).

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.84%), Janus Henderson Group PLC (5.38%), Sands Capital Management LLC (5.15%), Wellington Management Group LLP (3.98%), Orbimed Advisors LLC (3.26%) and State Street Corp (2.91%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Isan Chen, Jamie A Donadio, Jamie Christensen, Michael G Grey and Venbio Select Advisor Llc. View institutional ownership trends for Mirati Therapeutics.

MRTX stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, Two Sigma Advisers LP, Pictet Asset Management Ltd., Lord Abbett & CO. LLC, Ghost Tree Capital LLC, Rafferty Asset Management LLC, and Eaton Vance Management. Company insiders that have sold Mirati Therapeutics company stock in the last year include Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Isan Chen, and Michael G Grey. View insider buying and selling activity for Mirati Therapeutics.

MRTX stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Sands Capital Management LLC, Janus Henderson Group PLC, BlackRock Inc., Orbimed Advisors LLC, Geode Capital Management LLC, Nuveen Asset Management LLC, and Castleark Management LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, and Venbio Select Advisor Llc. View insider buying and selling activity for Mirati Therapeutics.

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRTX stock can currently be purchased for approximately $101.62.

Mirati Therapeutics has a market capitalization of $4.43 billion and generates $3.34 million in revenue each year. The biotechnology company earns $-213,260,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.

The official website for Mirati Therapeutics is www.mirati.com.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]